Medications

Patients with juvenile idiopathic arthritis are at high risk for uveitis in the first 24 months of discontinuing DMARD therapy, findings from the EULAR 2021 Virtual Congress indicate.

Etanercept is effective in the retreatment of patients with juvenile idiopathic arthritis who have a disease flare after previously achieving inactive disease on the biologic DMARD, research suggests.

An analysis of children with rheumatic diseases undergoing treatment with biologic agents has found no severe cases of COVID-19.

Individuals with active polyarticular juvenile idiopathic arthritis are more likely to respond to early treatment with etanercept plus methotrexate than with methotrexate alone, trial findings indicate.

Click through for more details on this announcement

Click through for more information on this expanded indication

Click through for details on this approval

The majority of patients with systemic or polyarticular-course juvenile idiopathic arthritis do not develop radiographic joint progression during the first 2 years of tocilizumab treatment, research shows.

Canakinumab monotherapy tapering, either through dose reduction or dose interval prolongation, is feasible in children with systemic juvenile idiopathic arthritis who achieve clinical remission, study findings indicate.

The addition of belimumab to standard therapy improves response rates and has manageable toxicity in patients with childhood-onset systemic lupus erythematosus, suggest findings from the phase 2 PLUTO study.

Click through for more details on this announcement

The ACR has issued guiding principles for the allocation of hydroxychloroquine, IL-1 and 6 antagonists, JAK inhibitors, and eculizumab during the COVID-19 pandemic.

Click through for more information

Timing of biologic DMARD use is important in the treatment of children with newly diagnosed polyarticular course juvenile idiopathic arthritis, with early use significantly more effective in reducing disease activity than delayed use, research shows.

Click through for more details on this expanded indication

Click through for further details